Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
08 nov. 2021 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. in Collaboration with Guardant Health Announces Initial Findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study
01 nov. 2021 08h00 HE
|
Kinnate Biopharma
BRAF clinical-genomic landscape research initiative to investigate real-world data from more than 175,000 patients across tumor types, patient demographics and treatment settings Preliminary analyses...
Kinnate Biopharma Inc. Announces Transition of Chief Scientific Officer
28 oct. 2021 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
07 oct. 2021 09h00 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. to Present Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
30 sept. 2021 16h30 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference
13 sept. 2021 08h00 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results
16 août 2021 16h05 HE
|
Kinnate Biopharma
Announced first patient dosed in Phase 1 trial evaluating KIN-2787 in patients with BRAF mutation-positive solid tumors Strengthened management team and Board of Directors with key appointments ...
Kinnate Biopharma Inc. to Participate in the 2021 Wedbush PacGrow Healthcare Conference
27 juil. 2021 08h00 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021
07 juil. 2021 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors
28 juin 2021 08h00 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...